CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.

CpG 寡脱氧核苷酸 (CpGs) 可以诱导抗肿瘤免疫反应，但也独特地引起直接淋巴瘤细胞毒性。为了提高 CpG 的递送和功效，我们利用与 B 类和 C 类 CpG 兼容的三乙烯修饰的 CpG 偶联金纳米颗粒 (tmCpG NP) 平台来治疗各种类型的淋巴瘤，包括弥漫性大 B 细胞淋巴瘤、高级别淋巴瘤、伯基特淋巴瘤和套细胞淋巴瘤。与游离 CpG 相比，两类 tmCpG NPs 通过细胞凋亡降低了人和鼠淋巴瘤细胞的活力，同时对树突细胞没有毒性作用。TmCpG NPs 增加了淋巴瘤细胞上 CD19、CD20 和 OX40 的表达。总体而言，我们引入了具有显着抗淋巴瘤作用的稳定 tmCpG NP 设计。